Alison R Novak, Mary E Bradley, Tyree H Kiser, Scott W Mueller
{"title":"抗唑曲霉和抗棘白菌假丝酵母-有什么治疗选择?","authors":"Alison R Novak, Mary E Bradley, Tyree H Kiser, Scott W Mueller","doi":"10.1007/s12281-020-00379-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review summarizes current treatment options for echinocandin-resistant <i>Candida</i> spp. (ERC) and azole-resistant <i>Aspergillus fumigatus</i> (ARAF), emphasizing recent <i>in vitro/in vivo</i> data, clinical reports, and consensus statements.</p><p><strong>Recent findings: </strong>Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task.</p><p><strong>Summary: </strong>When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.</p>","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":"14 2","pages":"141-152"},"PeriodicalIF":2.3000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12281-020-00379-2","citationCount":"8","resultStr":"{\"title\":\"Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?\",\"authors\":\"Alison R Novak, Mary E Bradley, Tyree H Kiser, Scott W Mueller\",\"doi\":\"10.1007/s12281-020-00379-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This review summarizes current treatment options for echinocandin-resistant <i>Candida</i> spp. (ERC) and azole-resistant <i>Aspergillus fumigatus</i> (ARAF), emphasizing recent <i>in vitro/in vivo</i> data, clinical reports, and consensus statements.</p><p><strong>Recent findings: </strong>Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task.</p><p><strong>Summary: </strong>When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.</p>\",\"PeriodicalId\":10813,\"journal\":{\"name\":\"Current Fungal Infection Reports\",\"volume\":\"14 2\",\"pages\":\"141-152\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12281-020-00379-2\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Fungal Infection Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12281-020-00379-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Fungal Infection Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12281-020-00379-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/3/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?
Purpose of review: This review summarizes current treatment options for echinocandin-resistant Candida spp. (ERC) and azole-resistant Aspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements.
Recent findings: Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task.
Summary: When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.
期刊介绍：
This journal intends to provide clear, insightful, balanced contributions that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of fungal infections. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as advances in diagnosis, current and emerging management approaches, and genomics and pathogenesis. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. Commentaries from well-known figures in the field are also provided, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
